期刊文献+

辽藁本抗动脉粥样硬化的实验研究 被引量:5

Experimental Study on Anti Atherosclerosis of Ligusticum jeholense
下载PDF
导出
摘要 目的评价辽藁本对动脉粥样硬化模型兔血脂、C反应蛋白等指标的调节能力,探讨其抗动脉粥样硬化的可能作用机制。方法采用免疫损伤法、球囊手术法、高脂饲料饲养法共同完成动脉粥样硬化动物模型,检测血脂指标、C反应蛋白、HE染色观察颈总动脉血管内皮组织病理形态学变化。结果辽藁本临床4倍等效剂量组(1.88 g生药/kg)与模型组比较,能够显著降低TC、LDL、C反应蛋白水平(P<0.05),辽藁本给药组显著改善白兔病理学形态学变化。结论辽藁本能够通过调节血脂、降低C反应蛋白,发挥抗动脉粥样硬化作用。 Objective To evaluate the regulatory ability of Ligusticum jeholense on blood lipid, C-reactive protein and other indexes in atherosclerotic model rabbits and explore the possible mechanism of its anti-atherosclerotic effect.Methods The atherosclerotic animal model was established by immune injury method, balloon surgery method and high-fat feed method. The changes of blood lipid, C-reactive protein and HE staining were observed.Results Compared with the model group, the levels of TC, LDL and C-reactive protein in the 4 times equivalent dose of Ligusticum jeholense group(1.88 g crude medicine/kg) was significantly reduced(P<0.05).The pathological and morphological changes were significantly improved in the treatment group.Conclusion Ligusticum jeholense can play an anti-atherosclerotic role by regulating blood lipid and reducing C-reactive protein.
作者 张昭华 庞敏 刘晶 武晓琳 刘禾 ZHANG Zhaohua;PANG Min;LIU Jing;WU Xiaolin;LIU He(Liaoning University of Traditional Chinese Medicine,Shenyang 110847,Liaoning,China;Liaoning Institute of Traditional Chinese Medicine,Shenyang 110034,Liaoning,China)
出处 《中华中医药学刊》 CAS 北大核心 2020年第3期78-80,I0017,共4页 Chinese Archives of Traditional Chinese Medicine
基金 十二五国家科技重大专项“重大新药创制”(2102ZX09303-017-001) 辽宁省自然科学基金指导计划(201602441)。
关键词 动脉粥样硬化 辽藁本 rabbit atherosclerosis Ligusticum jeholense
  • 相关文献

参考文献18

二级参考文献163

共引文献298

同被引文献51

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部